Alexion Pharmaceuticals (AXLN) Announces Interim Results from Phase I/II Trial of Samalizumab

December 6, 2010 8:20 AM EST Send to a Friend
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced Monday the the interim results of its first Phase I/II trial of samalizumab, which is evaluating the safety, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the first-in-class humanized monoclonal antibody.

The study showed that the the treatment was well tolerated at all doses, while exhibiting a dose-dependent biological and pharmacokinetic response, and exhibited initial evidence of anti-tumor activity.

“Samalizumab is designed to target the CD200 molecule, which is overexpressed in certain types of cancer. The early-stage clinical findings presented today are consistent with the predicted mechanism of action of samalizumab and support further study of this novel antibody,” said Stephen Squinto, Ph.D., Executive Vice President and Head of Research and Development at Alexion.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News

Add Your Comment